<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Introduction</td>
<td>Welcome</td>
</tr>
</tbody>
</table>
| 8:15  | Chawla Rosenfeld Developmental Therapeutics | Introduction  
A Case for Open-Source Drug Discovery  
Anti-angiogenic activity of JQ1 in Sarcomas  
The Sarcoma Data Portal: Making High Content Sarcoma Datasets Available For All Users  
Discussion/Q&A  
C. Khanna |
| 9:35  | SARC Career Development      | Career Development 2014 Program  
Genome-wide functional characterization of GIST: Strategies to maximize kinase-inhibitor response  
Exploiting Argininosuccinate 1 deficiency in Sarcoma  
Discussion/Q&A  
R. Gorlick & L. Helman |
| 10:20 | Break                        |                                                                             |
| 10:30 | SARC Clinical Trials         | Clinical Trials Update  
SARC012: Phase 2 trial of saracatinib in resected recurrent osteosarcoma  
SARC016: Phase 2 trial of bevacizumab & everolimus in unresectable or metastatic MPNST  
SARC020/EORTC: Phase 2b/3 study of trabectedin versus doxorubicin for first-line therapy of metastatic STS  
SARC021: Phase 3 trial of TH-302+doxorubicin versus doxorubicin in advanced/metastatic STS  
SARC022: Phase 2 trial of linsitinib in pediatric and adult wild-type GIST  
SARC023: Phase 2 trial of ganetespib & sirolimus in unresectable or metastatic MPNST  
SARC024: Phase 2 trial of regorafenib in refractory lipo, osteo and Ewing/Ewing-like sarcomas  
SARC025: Phase 1 trial of niraparib and temozolomide in incurable Ewing sarcoma  
S. Okuno  
M. Merchant  
L. Helman  
J. Butrynski  
W. Tap  
M. von Mehren  
L. Helman  
R. Maki  
S. Strauss |
| 11:15 | SARC Sarcoma SPORE           | Update SARC Sarcoma SPORE  
R. Pollock |
| 11:25 | Business                     | SARC Participant Policy  
D. Reinke |